Fidelity Investments’s Cognition Therapeutics CGTX Stock Holding History

Fidelity Investments’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1	Hold	1	–	–	﹤0.01%	5407
2025 Q4	$1	Hold	1	–	–	﹤0.01%	5407
2025 Q3	$1	Hold	1	–	–	﹤0.01%	5360
2025 Q2	$0	Hold	1	–	–	﹤0.01%	5352
2025 Q1	$0	Hold	1	–	–	﹤0.01%	5344
2024 Q4	$1	Hold	1	–	–	﹤0.01%	5511
2024 Q3	$0	Sell	1 -100	-99%	-$103	﹤0.01%	5520
2024 Q2	$168	Buy	101 +100	+10,000%	+$199	﹤0.01%	4937
2024 Q1	$2	Hold	1	–	–	﹤0.01%	5326
2023 Q4	$2	Hold	1	–	–	﹤0.01%	5395
2023 Q3	$1	Hold	1	–	–	﹤0.01%	5257
2023 Q2	$2	Hold	1	–	–	﹤0.01%	5335
2023 Q1	$2	Buy	+1	New	+$2	﹤0.01%	5234

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Fidelity Investments's CGTX Position: Q1 2026 in Review

Fidelity Investments held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #5407.

Fidelity Investments first reported a position in CGTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $168 in Q2 2024. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

Fidelity Investments held 1 share of Cognition Therapeutics worth $1 as of Q1 2026.
Fidelity Investments left its Cognition Therapeutics share count unchanged in Q1 2026.
Cognition Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5407 holding.
Fidelity Investments first reported a position in Cognition Therapeutics in Q1 2023 and has held it in 13 quarters since.
Fidelity Investments's Cognition Therapeutics position peaked at $168 in Q2 2024.
75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.